REGULATED PRESS RELEASE published on 02/25/2025 at 07:00, 1 year 2 months ago Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR) Biophytis to participate in ICFSR 15th International Conference on Frailty and Sarcopenia Research, presenting data on BIO101 for obesity-associated sarcopenia. Event in Toulouse, March 12-14 Biophytis Sarcopenia ICFSR BIO101 Obesity
PRESS RELEASE published on 02/25/2025 at 07:00, 1 year 2 months ago Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Sarclisa approved in Japan for newly diagnosed multiple myeloma patients, offering new treatment options based on positive IMROZ phase 3 study results Oncology Japan Multiple Myeloma Sarclisa IMROZ Study
PRESS RELEASE published on 02/25/2025 at 06:30, 1 year 2 months ago PSP Swiss Property achieves very good operating results and increases the dividend to CHF 3.90 per share. PSP Swiss Property achieves very good operating results and increases the dividend to CHF 3.90 per share. The real estate market remained robust with improvements in transaction markets Dividend Increase Annual Results Operating Results PSP Swiss Property Real Estate Market
PRESS RELEASE published on 02/25/2025 at 06:30, 1 year 2 months ago First half of the financial year 2024/25: Strong organic growth and margin expansion continue – strategy execution on track dormakaba Holding AG reports strong organic growth and margin expansion in the first half of the financial year 2024/25. The company's strategy execution is on track Financial Results Organic Growth Strategy Execution Margin Expansion Dormakaba Holding AG
PRESS RELEASE published on 02/25/2025 at 06:30, 1 year 2 months ago Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®. Approval for treating retinal diseases granted by UK's MHRA Regulatory Approval UK Biosimilar Formycon AHZANTIVE
PRESS RELEASE published on 02/25/2025 at 05:26, 1 year 2 months ago EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3Y Change of Director's Interest Notice Dexus Finance Pty Limited announces Change of Director's Interest Notice for Rhoda Phillippo. Appendix 3Y form filed to ASX for public disclosure Real Estate Dexus Finance Pty Limited ASX Release Appendix 3Y Change Of Director's Interest Notice
PRESS RELEASE published on 02/25/2025 at 02:20, 1 year 2 months ago UniDoc - Announces Filing of Amended and Restated Interim Management Discussion and Analysis UniDoc Health Corp. issues amended and restated management's discussion and analysis for clarifying disclosure following continuous disclosure review by the British Columbia Securities Commission British Columbia Securities Commission Management's Discussion And Analysis UniDoc Health Corp. Amended Clarifying Disclosure
PRESS RELEASE published on 02/25/2025 at 00:05, 1 year 2 months ago BluSky Carbon Announces Closing of Convertible Debenture Financing and Unit Offering BluSky Carbon Inc. closes non-brokered private placement of convertible debentures and completes Unit Offering, raising funds for business development Private Placement Business Development Convertible Debentures BluSky Carbon Inc. Unit Offering
PRESS RELEASE published on 02/25/2025 at 00:00, 1 year 2 months ago Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile Onco-Innovations Limited announces successful preclinical study results of its second-generation nanoparticle formulation of PNKP Compound, showing enhanced inhibitor delivery with minimal toxicity for potential cancer therapy Preclinical Study Cancer Therapy Onco-Innovations Limited Nanoparticle Formulation PNKP Compound
PRESS RELEASE published on 02/24/2025 at 22:15, 1 year 2 months ago Kingstone Announces Record Operating Profit and Growth for Fourth Quarter and Full Year 2024 Kingstone Companies, Inc. schedules conference call on March 14 for fourth quarter 2024 financial results. Company's preliminary financial performance highlights significant improvements in direct written premiums and operating income Financial Results Conference Call Kingstone Companies Inc. Preliminary Performance Direct Written Premiums
Published on 04/30/2026 at 01:35, 2 hours 57 minutes ago Kalo Gold Provides Update on High-Resolution Airborne Magnetic Survey at Vatu Aurum Project, Fiji
Published on 04/30/2026 at 01:15, 3 hours 17 minutes ago Credissential Announces Shares Consolidation
Published on 04/30/2026 at 00:00, 4 hours 32 minutes ago Redwood AI CEO Highlights Role of its AI Technology Within Aidos-Led B.C. Government's Track and Trace Pilot Program on Conversations That Matter TV Series, Featured in the Vancouver Sun
Published on 04/29/2026 at 23:58, 4 hours 34 minutes ago Roxmore Announces Filing of Meeting Materials for Upcoming Shareholders Meeting
Published on 04/30/2026 at 03:05, 1 hour 26 minutes ago Cohen & Steers Renames UCITS Preferred Securities Strategies as Hybrid Credit Strategies
Published on 04/29/2026 at 23:42, 4 hours 50 minutes ago H2APEX publishes figures for the 2025 financial year and provides positive outlook
Published on 04/29/2026 at 23:01, 5 hours 30 minutes ago Sirma Delivers 31% Revenue Growth in 2025 and Advances AI Platform Strategy
Published on 04/29/2026 at 22:15, 6 hours 16 minutes ago Amrize Grows Revenue 4.7% in First Quarter and Reaffirms 2026 Guidance
Published on 04/29/2026 at 22:05, 6 hours 27 minutes ago Evotec Announces New Nomination to Board of Directors
Published on 04/29/2026 at 18:15, 10 hours 16 minutes ago GUILLEMOT CORPORATION | AVAILABILITY OF THE UNIVERSAL REGISTRATION DOCUMENT INCLUDING THE 2025 ANNUAL FINANCIAL REPORT
Published on 04/29/2026 at 18:10, 10 hours 22 minutes ago Amemdment of the resolution n8 submitted to the AGM of 30 April 2026
Published on 04/29/2026 at 18:00, 10 hours 32 minutes ago Availability of the 2025 Universal Registration Document